Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/23/2025 | $8.00 | Underweight → Equal Weight | Wells Fargo |
| 4/17/2025 | $8.00 | Underweight | Wells Fargo |
| 2/6/2025 | $31.00 | Outperform | Wedbush |
| 12/6/2024 | $42.00 | Buy | H.C. Wainwright |
| 11/5/2024 | $48.00 | Buy | Rodman & Renshaw |
| 10/8/2024 | Overweight | Cantor Fitzgerald | |
| 10/8/2024 | $35.00 | Overweight | Morgan Stanley |
| 10/8/2024 | Buy | TD Cowen |
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharma
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset
8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
Wells Fargo upgraded Bicara Therapeutics from Underweight to Equal Weight and set a new price target of $8.00
Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00
Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset